- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04455698
Engaging and Activating Cancer Survivors in Genetic Services Study (ENGAGE)
Study Overview
Status
Conditions
Detailed Description
As childhood cancer survivors receive care locally from PCPs, the in-home, collaborative PCP model is designed to increase access to genetic services and uptake of genetic testing in childhood cancer survivors. In this model, individual survivors can access remote telegenetic services and genetic counselors will partner with PCPs to order genetic testing.
This study comprises of a 3-arm randomized Hybrid 1 Effectiveness and Implementation study in 360 CCSS survivors to evaluate the effectiveness of our in-home, collaborative PCP model of remote telegenetic services to increase uptake of cancer genetic testing in childhood cancer survivors compared to usual care options for genetic testing.
Aims are as follows:
To evaluate the effectiveness of our in-home, collaborative PCP model of remote telegenetic services to increase uptake of genetic testing at 6 months as compared to usual care among childhood cancer survivors who meet criteria for cancer genetic testing. Our primary outcome will be a composite variable indicating whether a person had pre-test counseling or genetic testing.
To evaluate the effectiveness of remote videoconferencing to provide greater increase in knowledge and decrease in distress and depression as compared to remote phone services, to examine the moderators of patient outcomes with remote telegenetic services, and to estimate intervention costs and incremental cost-effectiveness of the three study arms.
To conduct a multi-stakeholder, mixed-methods process evaluation to understand patient, provider and system factors associated with uptake of counseling and testing in our adapted in-home, collaborative PCP model and facilitators and barriers to uptake to provide recommendations for future implementation.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tara Henderson, MD
- Phone Number: 7737026808
- Email: thenderson@peds.bsd.uchicago.edu
Study Contact Backup
- Name: Mary A Allen
- Phone Number: 7738347165
- Email: mallen12@bsd.uchicago.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago Medical Center
-
Contact:
- Tara Henderson, MD
- Phone Number: 773-702-6808
- Email: thenderson@peds.bsd.uchicago.edu
-
Contact:
- Melissa Marx, MPH
- Phone Number: (773)702-2927
- Email: mailto:mmarx@peds.bsd.uchicago.edu
-
Principal Investigator:
- Tara Henderson, MD, MPH
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Angela Bradbury, MD
- Phone Number: 800-789-7366
- Email: angela.bradbury@pennmedicine.upenn.edu
-
Contact:
- Beth Wood
- Phone Number: 215-662-4303
- Email: elisabeth.wood@pennmedicine.upenn.edu
-
Principal Investigator:
- Angela Bradbury, MD
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105-3678
- Recruiting
- St Jude Children's Research Hospital
-
Contact:
- Aaron McDonald, PhD
- Phone Number: 901-595-6177
- Email: aaron.mcdonald@stjude.org
-
Contact:
- Shani Alston
- Email: Shani.Alston@STJUDE.ORG
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to understand and communicate in English or Spanish
- Currently residing in the US
Childhood Cancer Survivor Study Participant survivors of the following primary cancers:
- CNS tumor
- Sarcoma (except Ewing sarcoma)
- Hepatoblastoma
- Leukemia
Childhood Cancer Survivor Study Participant with a family history of a child with cancer:
- 2 or more malignancies in childhood (age 18 or younger)
- A first degree relative (parent or sibling) with cancer aged 45 or younger
- 2 or more second degree relatives with cancer aged 45 or younger (same side of family)
- Parents of the child with cancer are related (consanguinity)
- Other family history that meets NCCN criteria
- Able to communicate remotely through remote telegenetic platforms (phone or videoconference) with genetic counselors
Exclusion Criteria:
- Uncorrected or uncompensated speech defects that would lead to the participant being unable to communicate effectively with genetic counselor
- Currently residing in a US state or territory where genetic counselors are not licensed to provide care
- Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and task
- Participants who have already completed and received a clinically appropriate multi-gene panel genetic testing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Remote Telegenetics: TELEPHONE (ARM A)
Remote Phone Telegenetics: Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - TELEPHONE. |
Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor by Telephone.
|
Experimental: Remote Telegenetics: VIDEOCONFERENCING (ARM B)
Remote Videoconferencing Telegenetics: Participants with complete pre-test and disclosure counseling with a Genetic Counselor using remote services - VIDEOCONFERENCING. |
Participants will receive standard of care pre-test and disclosure genetic counseling with a genetic counselor using Videoconferencing Technology.
|
Experimental: USUAL CARE (ARM C)
Usual Care: Participants will receive referrals to genetic counseling providers, initiating services on their own. At 6 months, if participants have not sought and received genetic counseling services, they will be offered randomization to ARM A/ARM B. |
Participants in the usual care arm will receive usual care services depending on which referral method they choose and if they initiate services.
After a 6 month status survey, if they have not had genetic services through usual care they will be offered services and re-randomized to ARM A/ARM B.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who received testing or genetic counseling
Time Frame: 6 Months status survey (ARM C)
|
Primary composite outcome collected via remote services records-Yes/No (ARMS A/B)
|
6 Months status survey (ARM C)
|
Genetic Knowledge Scale
Time Frame: Baseline - Within 7 Days After Result Disclosure
|
Change in knowledge (ARMS A/B only).
Increased change score indicates increase in knowledge (better).
|
Baseline - Within 7 Days After Result Disclosure
|
Impact of Events Scale (IES)
Time Frame: Baseline - Within 7 Days After Result Disclosure
|
Change in Cancer Specific Distress (ARMS A/B only).
Score Range = 0-40.
Decreased score change indicates a decrease in distress (better).
|
Baseline - Within 7 Days After Result Disclosure
|
Patient-Reported Outcomes Measurement Information System (PROMIS)
Time Frame: Baseline - Within 7 Days After Result Disclosure
|
Change in Depression (ARMS A/B only).
Score Range = 4-20.
Decreased score change indicates a decrease in depression (better).
|
Baseline - Within 7 Days After Result Disclosure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Uptake of genetic counseling, testing, and identification of genetic carriers
Time Frame: 6 month status survey (ARM C)
|
Collected via remote services records (ARMS A/B)
|
6 month status survey (ARM C)
|
Patient Reported Outcomes Measurement Information Systems (PROMIS)
Time Frame: Baseline - Within 7 Days After Result Disclosure
|
Change in Anxiety (ARMS A/B only).
Score Range = 4-20.
Decreased score change indicates a decrease in anxiety (better).
|
Baseline - Within 7 Days After Result Disclosure
|
Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA)
Time Frame: Baseline - Within 7 Days After Result Disclosure
|
Change in Uncertainty (ARMS A/B only).
Score Range = 0-85.
Decreased score change indicates a decrease in uncertainty (better).
|
Baseline - Within 7 Days After Result Disclosure
|
Change in Health Behaviors (Selected from the Behavioral Risk Factor Surveillance System Questionnaire and the Health and Diet survey Dietary Guidelines Supplement)
Time Frame: Baseline - 6 Months After Result Disclosure
|
Change in performance of risk reductive and screening behaviors and communication of results - Yes/No responses (ARMS A/B only).
|
Baseline - 6 Months After Result Disclosure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tara O Henderson, MD, MPH, FASCO, University of Chicago
- Principal Investigator: Angela Bradbury, MD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CIRB21-0176
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Remote Telegenetic Counseling by Phone
-
Lata Medical Research Foundation, NagpurUnknownMalnutrition in Pregnancy | Other Disorders of Breast and Lactation Associated With ChildbirthIndia
-
Zhongshan People's Hospital, Guangdong, ChinaRecruitingPostoperative Complications | Telerehabilitation | Patient Reported Outcome Measures | Exercise Therapy | Lung Neoplasms, Non-Small Cell Lung CancerChina
-
University of PennsylvaniaCompletedAlzheimer Disease | Genetic Predisposition to Disease
-
Geisinger ClinicJohns Hopkins UniversityCompletedDiabetes Mellitus | Chronic Kidney Disease | AlbuminuriaUnited States
-
Atatürk UniversityCompletedPostoperative ComplicationsTurkey
-
Case Western Reserve UniversityNational Institutes of Health (NIH); American Heart AssociationCompletedStroke | Multiple Sclerosis | Rheumatoid ArthritisUnited States
-
Mayo ClinicUniversity of California, San Francisco; University of Minnesota; Alaska Native...CompletedPregnancy | Nicotine DependenceUnited States
-
Federal University of Juiz de ForaUniversity of Kansas Medical CenterCompletedTobacco Use Disorder | Tobacco Use CessationBrazil
-
University of Kansas Medical CenterNational Cancer Institute (NCI)Completed
-
Desmond Tutu HIV FoundationKarolinska Institutet; University of North Carolina, Chapel Hill; ViiV Healthcare and other collaboratorsCompletedHIV Infections | Covid19 | Health Care Utilization | Gender-based ViolenceSouth Africa